Recent studies have centered on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GLP agonists are widely employed for addressing type 2 diabetes mellitus, their emerging consequences on motivation circuits, specifically influenced by DA pathways, ar